

Background

In August 2019, Fujifilm Diosynth Biotechnologies (FDB) acquired a biologics manufacturing site owned by US-based Biogen in Hillerød for approximately \$890m. FDB is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies.

The facility became FDB's fourth biopharmaceutical manufacturing site in the world. The site in Hillerød extends over 247.000 m² with administration, warehouse buildings, laboratories and production halls.

Project Overview

In June 2020, Fujifilm announced a capital investment of 100bn yen (\$928m) in the first expansion of the site to double its existing drug substance manufacturing capacity and add fill/finish capabilities. The investment will also improve the facility's existing assembly, labelling and packaging services.

The first expansion includes the installation of six 20,000-litre (l) bioreactors, bringing the total to 12 20,000l bioreactors at the facility. A fully automated, cutting-edge fill/finish capability that can produce up to 35 million units a year will also be added for large-scale biologics production. Quantum have been a part of the project from the outset.

The project's construction of the first expansion was due to be completed by the end of 2023 and is now in the commissioning phase. When completed the first expansion is expected to generate 300 new jobs in Denmark.

